REMEGEN
- Country
- 🇭🇰Hong Kong, China
- Ownership
- Public
- Established
- 2008-07-04
- Employees
- 3.4K
- Market Cap
- -
- Website
- http://www.remegen.com
- Introduction
The company was co-founded in 2008 by Yantai Rongchang Pharmaceutical Co., Ltd., headed by Mr. Wang Weidong, and American scientist Dr. Fang Jianmin. The company is committed to discovering, developing, producing and commercializing first-of-its-kind, best-in-class biopharmaceuticals, and creating a number of new biological drugs with significant clinical va...
Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT06642545
- Locations
- 🇨🇳
Cance Hosoltal Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Single Dose Study to Investigate the Pharmacokinetics (PK) of Telitacicept Pre-filled Injection and Freeze-dried Powder Injection in Chinese Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 248
- Registration Number
- NCT06549959
- Locations
- 🇨🇳
The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China
🇨🇳West China Hospital of Sichuan University, Chengdu, Sichuan, China
🇨🇳Tianjin People's Hospital, Tianjin, Tianjin, China
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (RemeMG)
- Conditions
- Interventions
- First Posted Date
- 2024-06-13
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 180
- Registration Number
- NCT06456580
- Locations
- 🇺🇸
Port Charlotte, Florida Site, Port Charlotte, Florida, United States
🇺🇸Boca Raton, Florida Site, Boca Raton, Florida, United States
🇺🇸Miami, Florida Site, Miami, Florida, United States
A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2)
- Conditions
- Interventions
- First Posted Date
- 2024-06-13
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 350
- Registration Number
- NCT06456567
- Locations
- 🇺🇸
Hemet site, Hemet, California, United States
🇺🇸Menifee site, Menifee, California, United States
🇺🇸Rockford site, Rockford, Illinois, United States
To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 79
- Registration Number
- NCT06389006
- Locations
- 🇨🇳
Jiong Wu, Shanghai, Fudan University Shanghai Cancer Center, China
To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2
- Conditions
- Interventions
- First Posted Date
- 2024-04-22
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT06378242
- Locations
- 🇨🇳
Hunan Cancer hospital, Changsha, Hunan, China
🇨🇳Tongji Hospital, Wuhan, Hubei, China
🇨🇳West China Hospital, Chengdu, Sichuan, China
Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-01-26
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT06227156
- Locations
- 🇨🇳
The Third Medical Center of PLA General Hospital, Beijing, Beijing, China
🇨🇳Peking University First Hospital, Beijing, Beijing, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer
- First Posted Date
- 2024-01-26
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT06227117
- Locations
- 🇨🇳
Xiangya Hospital Central South University, Changsha, Hunan, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China
DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
- Conditions
- Interventions
- First Posted Date
- 2024-01-24
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT06221748
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
🇨🇳Harbin Medical University Cancer Hospital, Ha'erbin, Heilongjiang, China
DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-12-20
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT06178159
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China